A collaboration between Cenix BioScience of Germany and the USA's
Ambion has been formed to co-develop and market the first
commercially-available, human genome-wide library of small
interfering RNA sequences. RNA interference...
Pharmaceutical researchers used to begin their evaluation of drug
leads by looking at affinity and potency, but a
genomics/informatics-based research culture is now growing which is
starting to impinge on this classical mode, says...
Scientists in Australia report this week that they have developed a
powerful software modelling tool, MolSAR, which could have the
potential to reduce drug development costs by up to €28 million per
Dharmacon, a US supplier of RNA and RNA-interference research
products, announced today it has launched Cell Cycle siARRAY, a
collection of ready-to-use siRNA duplexes designed to knock down
112 genes involved in cell cycle regulation.
Venture capital investments in biotechnology and medical device
companies combined to total $4.7 billion (€4.4bn) in 2002, or 22
per cent of all investing, representing the highest proportion in
seven years, according to the MoneyTree...
Ireland's Elan Corp has inked a deal with Ingenium Pharmaceuticals
of Germany that will see the companies apply Ingenium's functional
genomics technologies to the discovery and development of novel
therapeutics for pain...
British Biotech, once the darling of the UK biotechnology industry
but now suffering the after-effects of a string of major drug
development failures, is having another go at bolstering its
pipeline via a merger with fellow UK company...
A series of new flow cytometry products will soon hit the market
with the announcement yesterday from US companies BD Biosciences
and Molecular Probes that, following a recent license agreement, BD
Biosciences Pharmingen has launched...
SC Biosciences is to be the exclusive distributor of sensitive
tools for drug discovery with the announcement this week that it
will distribute in vivo imaging technology in Japan for US company
Applied Biosystems group, the world's number one maker of
gene-analysing equipment, warned on Tuesday that it would report
lower-than-expected fiscal third-quarter revenue and earnings due
to deteriorating business conditions.